ClinVar Miner

Submissions for variant NM_058216.3(RAD51C):c.1006A>C (p.Thr336Pro)

gnomAD frequency: 0.00003  dbSNP: rs772344354
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000461973 SCV000550178 uncertain significance Fanconi anemia complementation group O 2023-12-26 criteria provided, single submitter clinical testing This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 336 of the RAD51C protein (p.Thr336Pro). This variant is present in population databases (rs772344354, gnomAD 0.007%). This missense change has been observed in individual(s) with breast cancer and/or ovarian cancer (PMID: 26261251, 34326862). ClinVar contains an entry for this variant (Variation ID: 409832). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RAD51C protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
GeneDx RCV000477986 SCV000565461 uncertain significance not provided 2018-11-14 criteria provided, single submitter clinical testing This variant is denoted RAD51C c.1006A>C at the cDNA level, p.Thr336Pro (T336P) at the protein level, and results in the change of a Threonine to a Proline (ACA>CCA). This variant has been observed in at least one individual with epithelial ovarian cancer (Song 2015). RAD51C Thr336Pro was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located in the region interaction with RAB51B, RAD51D,XRCC3 (Miller 2004). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether RAD51C Thr336Pro is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000564945 SCV000671882 uncertain significance Hereditary cancer-predisposing syndrome 2022-08-30 criteria provided, single submitter clinical testing The p.T336P variant (also known as c.1006A>C), located in coding exon 8 of the RAD51C gene, results from an A to C substitution at nucleotide position 1006. The threonine at codon 336 is replaced by proline, an amino acid with highly similar properties. This alteration has been reported in 1 of 3,429 patients with invasive epithelial ovarian cancer (EOC) and was not seen in any of the 2,772 controls or 2,000 additional unaffected women who were BRCA1/BRCA2 mutation-negative (Song H et al. J. Clin. Oncol., 2015 Sep;33:2901-7). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Color Diagnostics, LLC DBA Color Health RCV000564945 SCV000691211 uncertain significance Hereditary cancer-predisposing syndrome 2022-07-07 criteria provided, single submitter clinical testing This missense variant replaces threonine with proline at codon 336 of the RAD51C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with ovarian cancer (PMID: 26261251). This variant has also been identified in 3/282810 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.